↓ Skip to main content

Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes

Overview of attention for article published in New England Journal of Medicine, September 2007
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
4 news outlets
policy
6 policy sources
twitter
1 X user
patent
15 patents
wikipedia
2 Wikipedia pages
video
2 YouTube creators

Citations

dimensions_citation
624 Dimensions

Readers on

mendeley
314 Mendeley
citeulike
4 CiteULike
connotea
2 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Published in
New England Journal of Medicine, September 2007
DOI 10.1056/nejmoa075392
Pubmed ID
Authors

Rury R Holman, Kerensa I Thorne, Andrew J Farmer, Melanie J Davies, Joanne F Keenan, Sanjoy Paul, Jonathan C Levy

Abstract

Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic control is suboptimal, though evidence supporting specific insulin regimens is limited.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 314 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 1%
Spain 3 <1%
Japan 3 <1%
Italy 2 <1%
United Kingdom 2 <1%
Brazil 2 <1%
Ireland 1 <1%
South Africa 1 <1%
India 1 <1%
Other 5 2%
Unknown 290 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 54 17%
Other 51 16%
Student > Postgraduate 41 13%
Student > Master 29 9%
Student > Ph. D. Student 28 9%
Other 79 25%
Unknown 32 10%
Readers by discipline Count As %
Medicine and Dentistry 218 69%
Agricultural and Biological Sciences 20 6%
Pharmacology, Toxicology and Pharmaceutical Science 6 2%
Nursing and Health Professions 5 2%
Biochemistry, Genetics and Molecular Biology 4 1%
Other 19 6%
Unknown 42 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 February 2024.
All research outputs
#750,058
of 25,374,647 outputs
Outputs from New England Journal of Medicine
#8,214
of 32,472 outputs
Outputs of similar age
#1,158
of 83,712 outputs
Outputs of similar age from New England Journal of Medicine
#25
of 177 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,472 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 122.0. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 83,712 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 177 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.